Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2018

View Archived Issues

Synthesis method enables functional studies identifying antibiotic's promise

Researchers present preclinical data for PDE4B inhibitor VFP-B-3

ZHX2 acts as oncoprotein in clear cell renal carcinoma

Humanized midkine antibody demonstrates efficacy in experimental model of FSGS

First patient dosed in phase III clinical program for APL-2 in geographic atrophy

FDA approves initiation of phase II PHAST-TSC study for treatment of acute stroke

RedHill Biopharma concludes positive end-of-phase II meeting with FDA on Bekinda for IBS-D

New data support use of Akari Therapeutics' Coversin in inflammatory diseases

ORAIP: a potential biomarker of CTEPH

NIAID grant supports TechnoVax's development of universal influenza vaccine

Progenics reports topline phase III data on 1404 in low-grade prostate cancer

Verseon initiates phase I trial with anticoagulant VE-1902

University of Florida patents vincamine analogues

NIAAA to conduct phase II study of ANS-6637 for alcohol use disorder

TXNDC5 as a novel modulator of endothelial dysfunction and atherosclerosis

Galapagos and AbbVie Sarl present CFTR mutant correctors

Ono Pharmaceutical and Gilead Sciences identify new BTK inhibitors

First phase II data presented for AZD-4017 in idiopathic intracranial hypertension

Eisai divulges new hSTING agonists for cancer

Overcoming the biomolecular corona by pre-adsorption of antibodies to nanocarriers surface

Results of a first-in-human study of the JAK 1 inhibitor PF-04965842 in healthy subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...